JBIO vs RIGL: stock comparison and AI forecast
Jade Biosciences, Inc. (JBIO) and Rigel Pharmaceuticals Inc (RIGL) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
JBIO Jade Biosciences, Inc.
- Market Cap
- $897M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
RIGL Rigel Pharmaceuticals Inc
- Market Cap
- $854M
- P/E Ratio
- 2.7x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- JBIO and RIGL have similar market capitalizations ($897M and $854M).
- RIGL carries 0.18 times debt per unit of equity, against 0.07 times for JBIO.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | JBIO | RIGL |
|---|---|---|
| Market Cap | $897M | $854M |
| P/E Ratio | – | 2.74x |
| P/B Ratio | 2.04x | 1.92x |
| EPS | $-3.00 | $16.71 |
| Book Value/Share | $6.92 | $23.83 |
| Revenue/Share | – | $18.28 |
Profitability & Margins
| Metric | JBIO | RIGL |
|---|---|---|
| ROE | -42.9% | 69.0% |
| ROA | -40.0% | 58.6% |
| ROIC | -41.9% | 17.0% |
| Gross Margin | – | 91.2% |
| Operating Margin | – | 22.2% |
| Net Margin | – | 89.9% |
| EBT Margin | – | 22.1% |
| Tax Rate | -0.1% | -307.6% |
Financial Health
| Metric | JBIO | RIGL |
|---|---|---|
| Current Ratio | 14.93x | 2.39x |
| Quick Ratio | – | 2.19x |
| D/E Ratio | 0.07x | 0.18x |
| Financial Leverage | 1.07x | 1.18x |
| Interest Coverage | – | 57.0x |
| Working Capital | $440M | $110M |
Cash Flow
| Metric | JBIO | RIGL |
|---|---|---|
| Operating Cash Flow | -$124M | $90M |
| OCF Growth YoY | – | 31.9% |
Operational Efficiency
| Metric | JBIO | RIGL |
|---|---|---|
| Asset Turnover | – | 0.65x |
| Receivables Turnover | – | 6.0x |
| Inventory Turnover | – | 1.9x |
| Days Sales Outstanding | – | 60 days |
| Days Inventory | – | 193 days |
| Payables Period | – | 140 days |
| Cash Conversion Cycle | – | 114 days |
Income Statement
| Metric | JBIO | RIGL |
|---|---|---|
| Total Revenue | – | $342M |
| Operating Income | -$185M | $76M |
| Net Income | -$189M | $307M |
| R&D Expense | $157M | $55M |
| SG&A Expense | – | $128M |
| Cost of Goods Sold | – | $30M |
Dividend & Shareholder Information
| Metric | JBIO | RIGL |
|---|---|---|
| Shares Outstanding | 64M | 19M |
| Net Income Growth | – | 171.1% |
| EPS Growth | – | 232.2% |
JBIO vs RIGL: stock comparison and AI forecast
Which is bigger, JBIO or RIGL?
JBIO and RIGL have similar market capitalizations ($897M and $854M).
Which one does Intratio's AI model rank higher, JBIO or RIGL?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.